Surgical Apparel Manufacturing in European Union 2026: Industry Statistics & Trends

The surgical apparel manufacturing industry in the European Union involves the production of critical infection-prevention textiles such as sterile surgical gowns, drapes, scrubs, caps, and masks worn by healthcare professionals and patients. The sector is moving toward a highly integrated, single-use non-woven material dominance to comply with strict medical safety thresholds. Based on official disclosures from top European market operators, global medical device and textile leaders like Mölnlycke Health Care reported consolidated annual net sales of EUR 2,104 million in 2025, and the Paul Hartmann Group generated EUR 2,450 million in sales during the 2025 fiscal year, reflecting a steady d

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Surgical Apparel Manufacturing in European Union industry cover?

This industry encompasses the fabrication and sterilization of protective clothing and texturized barriers specifically designed for clinical and operating room settings. The scope includes both single-use disposable garments made from engineered synthetic polymers and traditional reusable woven cotton-polyester apparel engineered for high-temperature laundering. These products serve as critical barriers preventing the cross-contamination of infectious agents between surgical teams and patients.

• •Product categories comprise sterile surgical gowns, surgical drapes, cleanroom suits, lab coats, and face masks.
• •The technological boundary is defined by barrier efficacy standards, separating clinical surgical apparel from general occupational workwear.
• •Materials are predominantly non-woven synthetic fibers like polypropylene (PP) and polyethylene (PE) utilizing spunbond-meltblown-spunbond (SMS) structures.

Who operates in the industry and how is it structured?

The European Union's market structure is divided between multinational MedTech conglomerates that dominate high-volume hospital procurement contracts and a matrix of regional small-to-medium enterprises (SMEs) focused on specialized or customized clinical kits. Contract structures are highly centralized, governed by long-term regional public health procurement tenders that dictate volume and pricing. Manufacturing activities are split between localized specialized finishing facilities in western Europe and bulk textile conversion operations in eastern Europe or outsourced international hubs.

• •The supply chain relies on a steady flow of medical-grade synthetic resins and advanced non-woven rolls.
• •A regional transition is taking place with approximately 51% of surveyed EU textile SMEs increasing investments in green manufacturing as of recent data.
• •Industrial operators frequently utilize localized sterilization hubs employing ethylene oxide (EtO) or gamma irradiation before clinical deployment.

What drives demand in the industry?

Demand is heavily driven by the total volume of surgical procedures across EU member states and a heightened institutional focus on reducing Hospital-Acquired Infections (HAIs). According to the European Centre for Disease Prevention and Control (ECDC), millions of HAIs occur annually in European acute care facilities, making rigid adherence to barrier materials mandatory. Additionally, shifting demographic structures, notably an aging European population requiring more complex surgical interventions, create a reliable volume floor for clinical textile consumables.

• •The ECDC records approximately 8.9 million HAIs annually across European hospitals and long-term care institutions, driving strict protocol enforcement.
• •Clinical transitions favor single-use disposable gowns over reusable options due to lower cross-contamination risk and predictable lifecycle costs.
• •The implementation of rigid thermal disinfection guidelines by European national health services enforces strict material longevity requirements.

Who are the notable companies in the industry?

The competitive landscape in the EU is characterized by intense price and quality competition among a handful of major diversified medical suppliers and localized clinical textile firms. Companies differentiate themselves through superior barrier technology, supply chain resilience, and the inclusion of apparel in pre-assembled, procedure-specific surgical packs. Major market participants must balance high regulatory validation expenses against severe price pressures from low-cost overseas imports.

• •Mölnlycke Health Care AB, a prominent Sweden-based multinational owned by Investor AB, achieved net sales of EUR 2,104 million with an EBITDA of EUR 596 million in 2025.
• •The PAUL HARTMANN AG (Hartmann Group), based in Germany, reported preliminary global sales revenues of EUR 2.45 billion during the 2025 fiscal year.
• •Other real and highly active operators providing surgical apparel and infection management textiles within the EU include Ansell Limited, Medline Industries, and L&R (Lohmann & Rauscher).
• •Market participants face strict operational hurdles as structural shifts reduce the number of active finishing and formulation players in European medical textiles.

What are the recent trends and outlook?

Recent strategic shifts focus extensively on balancing strict sterile performance with environmental sustainability mandates. Manufacturers are investing heavily in bio-based synthetic polymers, circular take-back programs for non-contaminated apparel, and alternative chemical treatments. At the same time, regional market operators are restructuring internal costs and initiating operational transformation programs to defend margins against fluctuating raw material expenses.

• •Mölnlycke implemented its 'iMpact30+' transformation program in 2025 to optimize long-term efficiency and structural capacity across its business segments.
• •The Paul Hartmann Group advanced its targeted Transformation Program in 2025, yielding a preliminary adjusted EBITDA increase of EUR 15 million over the previous year.
• •Startups focusing on bio-based materials and sustainable textile fibers have risen across the EU ecosystem to target institutional green public procurement rules.

How is the industry regulated?

Compliance within the EU is exceptionally stringent and governed primarily by the European Medical Devices Regulation (MDR), which imposes extensive clinical evaluation and technical documentation protocols. Surgical apparel must conform to specific harmonized performance standards that categorize garments by performance level under various levels of fluid exposure. Furthermore, the handling of hazardous chemical treatments and mandatory waste collection frameworks add multi-layered legal obligations for regional manufacturers.

• •Surgical gowns and drapes are classified under the EU Medical Devices Regulation (MDR 2017/745) and must meet EN 13795 performance standards for barrier efficacy.
• •The European Chemicals Agency (ECHA) enforces stringent restriction updates under REACH, targeting chemical substances like specific fluoropolymers (PFAS) and nano-silver finishes in medical textiles.
• •European Union circular economy directives mandate the separate collection of textile waste, forcing manufacturers to design with post-use management in mind.

Government, statistical and trade sources used for this Claight analysis.

• Mölnlycke Health Care Integrated Annual Report 2025 ·
• HARTMANN GROUP Preliminary Financial Results 2025 ·
• European Centre for Disease Prevention and Control (ECDC) ·
• European Chemicals Agency (ECHA) ·
• Eurostat NACE Rev. 2 Framework ·
• European Industrial Ecosystems Monitor (European Commission 2024)